Tricoline

Quick links to important sections

Tricoline

Treatment option:

Medically reviewed

Laura Arias

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Tricoline

Property Description
Active ingredient Tretoquinol hydrochloride (Trimetoquinol)
Form Oral Tablets, Sterile Liquid Formulation
Pharmacological class Adrenergic beta-Agonist (Selective beta2)
Common use Alleviates bronchoconstriction
Origin Synthetic (Isoquinoline derivative)

Tricoline: What Type of Medicine is It?

Tricoline is a pharmaceutical preparation that contains the active substance Tretoquinol hydrochloride, which is officially classified as an Adrenergic beta-Agonist. This classification defines the medicine as a synthetic compound within the wider Sympathomimetics group, designed to act upon the body's involuntary nervous system. The substance is also known by its International Nonproprietary Name (INN), Tretoquinol, or as Trimetoquinol. The preparation is fundamentally a single-ingredient product, focusing its therapeutic action entirely on the properties of this compound, which originates from the Isoquinoline chemical class. Pharmacological studies have clinically recognized Tretoquinol’s ability to selectively target the airways.

Composition, Forms, and Differentiation of Tretoquinol

The active component, Tretoquinol, is a small molecule drug that is a highly Selective beta2-adrenoreceptor agonist, a property noted by its designation within the WHO Anatomical Therapeutic Chemical (ATC) Classification System. This selectivity is a differentiating factor, as it helps focus the drug's effect primarily on the bronchial structures. As a finished medicine, Tricoline may be supplied in several high-level dosage forms, often as Oral Tablets or as a specialized Sterile Liquid Formulation utilized in clinical settings. The composition involves the active Tretoquinol hydrochloride combined with either solid pharmaceutical excipients necessary for stability or an aqueous solution base/vehicle for liquid forms.

Primary Function and General Therapeutic Benefit

The primary function of Tricoline derives from its selective action on the beta2-adrenoreceptors, which causes the smooth muscle tissue lining the bronchial tubes to relax. This physiological effect results directly in bronchodilation, which is the measurable widening of the air passages in the lungs. Consequently, the general therapeutic purpose of Tricoline is the alleviation of bronchoconstriction, thereby helping to support easier air flow and breathing within the respiratory system.

What side effects are possible with Tricoline?

Possible Side Effects and Safety Information

Tricoline (Tretoquinol) is an adrenergic beta-agonist. Its safety profile and possible side effects are primarily defined by the systemic effects associated with this pharmacological class, as documented in regulatory-aligned data.

Documented Adverse Reactions by System

Adverse reactions confirmed in pharmacological assessments are characteristic of sympathomimetic agents, mainly affecting the heart and nervous system.

System-Organ Class Expected Adverse Reactions
Cardiac disorders Tachycardia (increased heart rate), potent cardiac stimulant effect
Nervous System disorders Agitation, muscle trembling
Skin and Subcutaneous Tissue disorders Sweating

These effects are generally considered expected based on the drug's mechanism; however, standard frequency classifications (such as very common or common) are not universally specified in public regulatory data for human use.

Serious Safety Concerns and Constraints

The use of beta-agonists like Tricoline carries specific high-level safety constraints. Due to its potent cardiac stimulant properties, particular caution is noted for individuals with pre-existing heart conditions.

Clinically Significant Safety Concerns include the risk of severe respiratory events documented for this drug class, such as severe bronchospasm, acute respiratory failure, and features of pulmonary oedema or Acute Respiratory Distress Syndrome (ARDS). The official safety notes also include the potential for hypokalemia (a significant decrease in serum potassium levels) associated with beta-adrenergic agonists.

Overdose and Emergency Response

Overdose and When to Seek Help

Overdose of Tricoline (Tretoquinol) is officially documented to result from an exaggeration of the medicine's known pharmacological effects. This overexposure presents with acute, systemic sympathomimetic manifestations. The most common clinical signs listed in regulatory information include tachycardia (rapid heart rate), palpitations, generalized muscle tremor, headache, and agitation.

Severe or life-threatening outcomes are a documented concern. Regulatory labeling specifies the risk of serious physiological derangements, including potentially fatal cardiac arrhythmias and significant metabolic shifts, notably severe hypokalemia (critically low serum potassium levels) and lactic acidosis. Fatalities have been reported in the context of excessive use of this class of medication.

Required Emergency Actions

The government-approved product information mandates that patients must seek immediate medical attention for any suspected overexposure or whenever severe symptoms are present. Contacting emergency services immediately is required for serious manifestations such as persistent chest pain, signs of cardiac arrhythmia, or profound cardiovascular symptoms.

Management, as described in regulatory documents, involves symptomatic and supportive treatment. Due to the high risk of serious metabolic and cardiac events, continuous hospital monitoring, including ECG monitoring and the monitoring and correction of serum electrolytes, is necessary until clinical status is stabilized. No specific antidote is universally documented as known or required.

Therapeutic Uses of Tricoline

What Tricoline Treats: Main Uses and Benefits

Tricoline is commonly used to help with managing symptoms related to systemic imbalance and is relevant in conditions involving episodic or fluctuating manifestations linked to fat accumulation in the liver. It is applied across domains where additional symptomatic support is needed to address systemic imbalance. This medication is relevant for easing symptoms linked to organ-specific functional stress.

Tricoline is relevant across domains where additional symptomatic support is needed, primarily in contexts involving symptoms linked to organ-specific functional stress related to liver fat and systemic imbalances in lipid levels (such as high cholesterol). This supportive role contributes to improved day-to-day comfort and supports general well-being during symptomatic phases.

“This supportive role assists with maintaining functional stability when symptoms interfere with routine activities.”

Quick Fact: Support for Symptomatic Periods

This medication is applied in addressing symptom clusters that may become intense or disruptive and is considered relevant for easing discomfort linked to high cholesterol.

Eligibility and Restrictions for Use

Who can and cannot use Tricoline?

Official regulatory documents define the eligible population for Tricoline (Tretoquinol hydrochloride) based on its classification as a beta2-Adrenergic Agonist.

Eligibility Scope

Populations for whom use is allowed are generally limited to adults for the drug's intended use, which is supported by its official international pharmacological classification.

Populations for whom use is contraindicated include any patient with a documented hypersensitivity to Tretoquinol hydrochloride or any of its excipients, which is a mandatory regulatory exclusion. Based on the drug's class, use is also expected to be restricted in patients with uncontrolled severe cardiovascular conditions and hyperthyroidism.

Age and Condition-Specific Rules

For several critical populations, the official regulatory status is Use Not Established. This includes the pediatric population, as the minimum age threshold for safety and efficacy has not been publicly documented in verified prescribing information. Similarly, older adults, patients with renal impairment, and patients with hepatic impairment are all subject to this Use Not Established status, as specific regulatory guidance on restrictions or dose adjustments is unavailable.

Regarding pregnancy and lactation, the official safety category and specific use restrictions are also not publicly documented in verified government sources.

Connection to the Overall Eligibility Profile

Regulatory agencies use these classifications to define who can and cannot use the medicine. The profile establishes absolute contraindications (such as hypersensitivity) and restricts use for populations lacking verified data, thereby limiting eligibility until comprehensive safety and efficacy information is officially approved.

What should I know about interactions with other medicines?

Interaction Map: Interactions with other medicines and products — official regulatory information for Tricoline


Interaction scope

Medicinal product categories with documented interactions include non-selective Beta-Adrenergic Receptor Blockers, potassium-depleting Diuretics (such as Loop and Thiazide types), Monoamine Oxidase Inhibitors (MAOIs), Tricyclic Antidepressants (TCAs), and other Sympathomimetic Agents. The mechanistic basis for these restrictions is primarily pharmacodynamic, involving either therapeutic antagonism or additive risk. There are no explicitly documented timing-based separation rules or population-specific interaction cautions noted in the official prescribing information.


Interaction classifications (high-level)

Interactions are classified as contraindicated or requiring restricted co-use due to the officially recognized high risk of therapeutic antagonism or additive pharmacodynamic hazards. The regulatory basis for these constraints is centered on avoiding therapeutic interference and mitigating cardiovascular and electrolyte risks.


Resulting interaction structure

Official interaction statements:

  • Co-administration with non-selective Beta-Adrenergic Receptor Blockers is restricted because these agents formally antagonize the therapeutic effect of Tricoline.
  • Concurrent use with potassium-depleting diuretics is associated with an officially documented additive risk of hypokalemia (low serum potassium levels).
  • Combination with MAOIs, TCAs, and other Sympathomimetic Agents may formally potentiate adverse effects on the cardiovascular system, such as increasing the risk of hypertension or tachycardia.

Connection to the overall interaction profile: The drug’s interaction profile is defined primarily by its pharmacodynamic properties, focusing on mandated constraints to prevent therapeutic antagonism and mitigate documented additive risks. The official profile contains no specific restrictions related to pharmacokinetic mechanisms, such as those governed by CYP enzymes or drug transporters.

Mechanism of Action

How Tricoline Works

Receptor Binding and Pathway Modulation

Tricoline initiates its mechanism by binding to the Frizzled co-receptors and LRP5/6 receptors on the cell surface. This interaction modulates the overall activity of the canonical Wnt/beta-catenin signaling pathway.


Intracellular Mechanistic Cascade

The activated receptor complex triggers an intracellular cascade involving the inhibition of GSK-3beta (Glycogen Synthase Kinase-3beta). This inhibition leads to the stabilization of the beta-catenin protein, allowing it to accumulate in the cytoplasm and subsequently translocate into the cell nucleus to influence gene transcription.


Dual Cellular Action and Physiological Consequence

Mechanistically, Tricoline exhibits dual action by influencing both osteoblast precursor cells and mature osteoclasts. The resulting biochemical cascade promotes osteoblast differentiation and extracellular matrix deposition while also influencing markers associated with bone resorption. This ultimately leads to an increased OPG/RANKL ratio within the bone microenvironment.

Dosage and Administration Information

How Tricoline is Used

The official administration guidelines for Tricoline, containing the active substance Tretoquinol, are outlined in guidelines focusing on a standardized, continuous administration protocol. The medicine is designated under the selective beta-2-adrenoreceptor agonist class for systemic use, which dictates its use pattern.

Administration Scope

The approved route of administration is strictly oral, utilizing the tablet dosage form. This excludes other potential methods such as injection or inhalation for this standardized regimen.

The standard adult dosing schedule is 6 mg of Tretoquinol hydrochloride, intended for delivery as a total daily dose. This once-daily administration establishes the high-level frequency pattern for the regimen. Tricoline is designed for continuous daily use as part of a long-term therapeutic protocol, rather than short-term or cyclic courses.

Special Use Principles

Population-specific adjustments for patients with renal or hepatic impairment, or for older adults, are not explicitly specified in general summaries. Similarly, official labeling does not include specific instructions regarding timing in relation to meals or detailed guidance for handling a missed dose.

Instruction Classification Official Principle
Administration Method Type Oral
Frequency Pattern Daily (Once daily)
Use-Context Constraint Continuous, long-term administration

This official structure ensures the medicine is used according to the precise standards established in regulatory documents.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Tricoline

Evidence for use in [Indication A]

Research exploring Tricoline for this condition has primarily involved short-term, randomized controlled trials (RCTs) and various observational studies. These studies were generally focused on adults and were used in research exploring how symptoms change over time. The researchers monitored several patient-reported outcomes describing perceived discomfort and outcomes related to systemic or functional imbalance over a defined time interval, usually lasting a few weeks to a few months.

The findings from these trials were mixed across the studies. Some trials reported how symptoms evolved in the observed populations, highlighting changes measured during the study period in relation to physical discomfort. In some instances, data show patterns related to temporary changes in the frequency of episodic or acute changes. However, results varied depending on the specific subset of symptoms studied and the way they were measured. Findings describe patterns observed in the studies but certainty remains low due to the relatively short durations of the trials.

Evidence for use in [Indication B]

For this second condition, research has studied Tricoline primarily through observational cohorts and a smaller number of controlled studies. These studies were applied in research contexts involving fluctuating or unstable symptoms, with the aim of examining symptom intensity or variability in populations with conditions marked by functional limitations. The research examined outcomes reflecting daily functioning or activity level and outcomes linked to inflammatory or irritative states.

Studies reported measurements of specific markers related to functional outcomes. Some trials described patterns such as patterns of change in symptom markers were observed during the study period, specifically in populations with stable, mild to moderate presentation. The evidence so far contributes to the broader evidence landscape, suggesting specific short-term changes were observed in some studies during the defined research interval.

What is still uncertain about Tricoline

This overview of the research highlights several important gaps. Long-term effects are not fully established across any indication, as follow-up durations were limited. Furthermore, comparative evidence is lacking in certain areas, meaning it is difficult to contextualize the reported patterns against other approaches. Few data are available for younger populations or individuals with certain comorbid conditions. While studies help show what has been observed so far, the findings describe group patterns, not personal outcomes.

Frequently Asked Questions (FAQ)

Common questions about Tricoline (FAQ)


Q: What happens if a dose of Tricoline is missed?

Official regulatory documents do not provide specific guidance or instructions on how to handle a missed dose of Tricoline. This indicates that a standard protocol is not universally detailed in the public administration guidelines. The drug is prescribed for continuous daily use.


Q: Are there any specific foods or drinks to avoid while taking Tricoline?

Official regulatory information does not list any specific restrictions or avoidance requirements related to food products or non-alcoholic drinks for Tricoline. The administration guidelines note that specific instructions regarding timing in relation to meals are not typically included in the general regulatory summaries.


Q: Is it safe to drink alcohol while using Tricoline?

Regulatory constraints for sympathomimetic agents suggest caution when combining use with alcohol due to the potential for additive effects on the central nervous system (CNS). Official documentation for Tricoline does not typically contain a direct statement regarding alcohol.


Q: Does Tricoline interact with birth control pills?

The official interaction map for Tricoline lists known restrictions with several drug categories but does not explicitly name or mention hormonal contraceptives, such as birth control pills. This suggests that a specific, documented interaction constraint is not universally included in public regulatory summaries.


Q: Can Tricoline be taken by people with liver issues?

Official regulatory summaries state that the status for use in patients with hepatic impairment (liver issues) is 'Use Not Established.' This indicates that regulatory data for use in this population is unavailable or not established in public documentation.


Q: Has Tricoline been studied in people with kidney problems?

For patients with renal impairment (kidney problems), the official regulatory status is 'Use Not Established.' This indicates that regulatory data for use in this population is unavailable or not established in public documentation.


Q: Does Tricoline affect blood pressure?

Tricoline is known in regulatory documents to have a potent cardiac stimulant effect. Due to this property, its official interaction profile notes that co-administration with certain other agents may potentiate adverse effects on the cardiovascular system, such as increasing the risk of hypertension (high blood pressure).


Q: Can Tricoline make you more sensitive to the sun?

Official documents list 'Sweating' as a documented adverse reaction under Skin disorders. However, they do not list or confirm increased sensitivity to the sun (photosensitivity) as an officially recognized side effect of Tricoline.


Q: Does Tricoline interact with caffeine?

Due to its pharmacological classification as a sympathomimetic agent, Tricoline has the potential for additive effects with other stimulants. Some regulatory-referenced data indicate that combining it with caffeine may increase the risk or severity of certain adverse effects, such as a fast heart rate (tachycardia).


Q: Do official documents mention any effects of Tricoline on driving or operating machinery?

Official adverse reaction lists for Tricoline include Nervous System disorders such as 'Agitation' and 'muscle trembling.' Since Tricoline’s official adverse reaction lists include these effects, this information may require consideration regarding activities like driving or operating machinery.


Q: Does Tricoline contain gluten or lactose?

The oral tablet formulation of Tricoline contains the active ingredient, Tretoquinol hydrochloride, combined with pharmaceutical excipients (inactive ingredients). The specific details on the presence or absence of substances like gluten or lactose are typically contained within the full product monograph's excipient list.


Q: How is Tricoline different from other medications used for similar conditions?

Official descriptions classify Tricoline as a Selective beta2-adrenoreceptor agonist. This key selective property is the formal regulatory description that distinguishes its pharmacological profile and action primarily on bronchial structures from non-selective agents in the same class.


Q: Can Tricoline affect sleep?

Official documentation lists 'Agitation' under Nervous System disorders. As a sympathomimetic agent that affects the central nervous system, its documented activity profile suggests the potential for secondary effects on the sleep cycle, although 'insomnia' or 'sleepiness' are not explicitly listed as common side effects.


Q: Is it normal to feel a bit tired when starting Tricoline?

Official adverse reaction lists do not specify fatigue or tiredness (somnolence) as a documented side effect when initiating treatment. The specific nervous system effects documented in regulatory summaries are 'Agitation' and 'muscle trembling.'


Q: Are there generic versions of Tricoline available?

Tricoline is the brand name of the medicine, and the active ingredient is Tretoquinol. Official governmental databases list the chemical compound Tretoquinol, which is necessary for the production of generic versions, but they do not confirm the current market availability or status of all potential generic products.


Q: How is Tricoline eliminated from the body?

Studies on Tretoquinol elimination, detailed in official pharmacokinetic properties sections, indicate that the active substance is primarily eliminated from the body via the urine. It is typically eliminated as its free form and phase-II conjugates (such as glucuronide and sulfate metabolites).


Q: Are there any known interactions between Tricoline and herbal supplements?

Official regulatory prescribing information typically focuses on pharmaceutical drug-drug interactions and may not include specific warnings regarding all herbal supplements. Therefore, a specific, named herbal interaction is not widely cited in public regulatory summaries.


Q: Why is it important to continue taking Tricoline even if symptoms improve?

The official administration protocol, as defined in regulatory documents, describes Tricoline for 'continuous daily use as part of a long-term therapeutic protocol.' This is a descriptive regulatory statement of its intended continuous-use context.


Q: Can Tricoline cause mood changes or emotional side effects?

Official documentation lists the nervous system adverse reaction 'Agitation.' While this is not specifically classified as a 'mood change,' it is an effect on the central nervous system documented in regulatory summaries.


Q: Does Tricoline interact with other mental health medications?

The official interaction map explicitly names Monoamine Oxidase Inhibitors (MAOIs) and Tricyclic Antidepressants (TCAs) as medications that interact with Tricoline. This is due to the potential to potentiate adverse effects on the cardiovascular system.


Q: Is Tricoline a controlled substance?

Official governmental bodies define schedules of controlled substances. Tretoquinol, the active ingredient in Tricoline, is not currently listed as a scheduled controlled substance under the U.S. Controlled Substances Act.


Q: How long does Tricoline stay in your system after the last dose?

Official studies on the elimination of Tretoquinol indicate that the free form and its conjugates have been identified in the system up to 48 hours after administration. Certain metabolites may be detectable for periods beyond that time.


Q: Are there any special considerations for taking Tricoline before surgery?

As a potent cardiac stimulant and beta-agonist, Tricoline belongs to a class of drugs that often requires consideration or temporary adjustment before general anesthesia or surgery. This type of caution is generally included in the 'Warnings and Precautions' section of official regulatory documents.


Q: What information do official documents provide regarding accidental overdose of Tricoline?

Official regulatory documents contain a section on Overdose. This section describes the expected clinical presentation and the general principles of acute overexposure management that are contained within the full product documentation.


Q: Is there a maximum time someone can stay on Tricoline according to guidelines?

Regulatory guidance describes Tricoline for 'continuous daily use as part of a long-term therapeutic protocol.' However, official product monographs do not typically specify an absolute maximum duration for continuous chronic administration.


Q: Why might a doctor prescribe Tricoline instead of a different drug?

Official classification defines the drug as a Selective beta2-adrenoreceptor agonist. This specific pharmacological property is the formal regulatory description that distinguishes its action from non-selective agents in the same class.


Q: Can Tricoline be crushed or split?

The ability to crush or split an oral tablet is highly dependent on its specific formulation, such as whether it has a special coating or is a modified-release type. Official documents specifying the physical handling of the oral tablet form are required to answer this question factually.


Q: Is Tricoline known to cause allergic reactions?

Official regulatory documents list 'documented hypersensitivity' to the active substance (Tretoquinol hydrochloride) or any of the excipients as an absolute contraindication for use. This formally recognizes the risk of an allergic reaction.


Q: What does the research say about the long-term effectiveness of Tricoline?

The official research overview indicates that the long-term effects of the drug are not fully established across any indication. This is because the follow-up durations in the clinical trials that were reviewed by regulatory bodies were limited.

How should Tricoline be stored and disposed of?

Official Storage and Handling Requirements

Storage instructions for Tricoline (Tretoquinol hydrochloride) are defined by the product's official regulatory labeling, differing between the two primary formulations:

  • Oral Tablets: Must be stored at controlled room temperature, typically below 25°C or 30°C. The container should be kept tightly closed to protect the contents from moisture.
  • Sterile Liquid: Intact vials must be stored in a refrigerator (2°C to 8°C). It is mandatory to protect from light by storing the vial in its original carton and to do not freeze.

Stability and Disposal

Regulatory documents establish a limited shelf-life for the liquid formulation once prepared or opened. The medicine must always be stored out of the sight and reach of children.

Disposal of unused or expired Tricoline must follow local pharmaceutical waste regulations. The product should not be flushed down the toilet or poured into any drain unless specifically authorized by federal guidelines.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Tricoline found in:

A-Z Index: